STOCK TITAN

Wave Life Scienc Stock Price, News & Analysis

WVE Nasdaq

Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology leader advancing RNA medicines through its proprietary PRISM platform. This page provides investors and researchers with timely updates on the company's stereopure oligonucleotide therapies targeting genetic disorders.

Access the latest press releases covering clinical trial progress, regulatory milestones, and scientific advancements. Our curated collection includes updates across WVE's pipeline, including programs for Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and neurological conditions.

Key news categories include:
• Clinical development updates
• Strategic research collaborations
• Regulatory pathway announcements
• Scientific publication highlights

Bookmark this page for direct access to primary source materials about WVE's innovative approach to RNA editing and antisense technologies. Monitor critical developments in precision genetic medicine through verified company communications.

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focusing on RNA medicines, has announced its upcoming second quarter 2024 financial results release. The company will host a live webcast and conference call on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss the results and provide business updates.

Investors and interested parties can access the webcast through the 'Investor Events' section of the company's website. Analysts wishing to participate in the Q&A session can join via a provided audio conferencing link. An archived version of the webcast will be available on the company's website following the live event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.81%
Tags
-
Rhea-AI Summary

Wave Life Sciences announced positive results from their Phase 1b/2a SELECT-HD trial for WVE-003, a therapeutic for Huntington's disease (HD). The trial showed a statistically significant 46% reduction in mutant huntingtin (mHTT) protein in the cerebrospinal fluid compared to placebo, while preserving wild-type huntingtin (wtHTT) protein. The drug was generally safe and well-tolerated. These results validate Wave's RNA medicines platform and support potential accelerated approval discussions with regulators. Wave plans to continue developing WVE-003 and other therapies targeting HD and other conditions, with anticipated data releases in 2024 and 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags
-
Rhea-AI Summary

Wave Life Sciences announced upcoming presentations at two significant conferences in June 2024. At the Obesity & Weight Loss Drug Development Summit, they will discuss their INHBE program, targeting fat burning and muscle preservation. At the RNA Editing Summit, they will present their RNA editing capabilities for mRNA correction, highlighting their WVE-006 program for Alpha-1 antitrypsin deficiency. The company aims to demonstrate the potential of their RNA medicines in treating both rare and common diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences
Rhea-AI Summary

Wave Life Sciences, a clinical-stage biotech company, will present at the 2024 Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 7:30 a.m. ET, and will feature a presentation by Paul Bolno, the CEO. A live webcast will be accessible through the Investor Relations page on the company's website, with a replay available for a time. This event provides insight into the company's progress in RNA medicines aimed at transforming human health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences reported its first quarter 2024 financial results and provided updates on its innovative RNA medicines pipeline and collaborations. The company remains on track for key data sets, including proof-of-mechanism data in AATD patients, INHBE program for obesity, GSK collaboration programs, allele-selective HD program, and registrational FORWARD-53 trial in DMD. Wave has cash and cash equivalents of $181 million and additional $12 million earned under GSK collaboration. The company is well-positioned for future growth and leadership in RNA medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
-
Rhea-AI Summary

Wave Life Sciences announced the appointment of Dr. Erik Ingelsson as Chief Scientific Officer. Dr. Ingelsson will drive Wave's therapeutic portfolio strategy by leveraging genetics and genomics capabilities to advance RNA medicines. His experience in genetic insights and drug discovery will shape Wave's transformative RNA medicines, including the INHBE program for obesity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
management
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) will be represented by Paul Bolno, MD, MBA, at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on May 14, 2024. The event will feature an analyst-led fireside chat discussing the company's RNA medicines. The presentation will be live webcasted and available for replay on the Wave Life Sciences Investor Relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) will host a webcast and conference call on May 9, 2024, to discuss their first quarter financial results and business updates. The event can be accessed on the company's website. Analysts can participate in the Q&A session via an audio conferencing link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
-
Rhea-AI Summary

Wave Life Sciences announced the approval of its first clinical trial application for the RestorAATion-2 trial of WVE-006 in individuals with Alpha-1 Antitrypsin Deficiency (AATD). WVE-006, a first-in-class RNA editing oligonucleotide, aims to correct disease-causing RNA mutations in AATD patients. The company is on track to deliver proof-of-mechanism data in 2024, showcasing the potential of RNA editing technology in treating genetic diseases like AATD. Wave Life Sciences continues to advance its RNA editing pipeline with a focus on GalNAc-hepatic and extra-hepatic targets, utilizing its proprietary 'edit-verse' platform for target identification and development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
none

FAQ

What is the current stock price of Wave Life Scienc (WVE)?

The current stock price of Wave Life Scienc (WVE) is $7.32 as of September 30, 2025.

What is the market cap of Wave Life Scienc (WVE)?

The market cap of Wave Life Scienc (WVE) is approximately 1.1B.
Wave Life Scienc

Nasdaq:WVE

WVE Rankings

WVE Stock Data

1.14B
134.09M
15.79%
86.89%
10.88%
Biotechnology
Pharmaceutical Preparations
Link
Singapore
SINGAPORE